Comorbidities and eligibility for KarMMa trial
| . | Total . | Age of <65 y . | Age of ≥65 y . |
|---|---|---|---|
| Number of patients, n (%) | 156 | 81 (51.9) | 75 (48.0) |
| Comorbidity burden | |||
| No comorbidities | 7 (4.3) | 5 (5.9) | 2 (2.5) |
| ≥1 comorbidity | 149 (95.7) | 76 (94.0) | 73 (97.5) |
| Total comorbidities | 147 | 87 | 102 |
| Frequent comorbidities (>10% in patient population) | |||
| Neuropathy | 80 (51.2) | 36 (44.4) | 44 (58.6) |
| Hypertension | 56 (35.8) | 23 (28.3) | 33 (44.0) |
| Pain | 53 (33.9) | 23 (28.3) | 30 (40.0) |
| Diabetes | 28 (17.9) | 13 (16.0) | 15 (20.0) |
| Hyperlipidemia | 26 (16.6) | 10 (12.3) | 16 (21.3) |
| Immunodeficiency | 25 (16.0) | 10 (12.3) | 15 (20.0) |
| Renal dysfunction∗ | 22 (14.1) | 9 (11.1) | 13 (17.3) |
| GERD | 18 (11.5) | 10 (12.3) | 8 (10.6) |
| Anxiety | 18 (11.5) | 11 (13.5) | <10% |
| Depression | <10% | 11 (13.5) | <10% |
| Arthritis | <10% | 9 (11.3) | <10% |
| Anemia | <10% | <10% | 9 (12.0) |
| Hypothyroidism | <10% | <10% | 8 (10.6) |
| OSA | <10% | <10% | 8 (10.6) |
| Did not meet KarMMa trial criteria | 111 (71.1) | 53 (65.4) | 58 (77.3) |
| Individual KarMMa trial exclusion criteria | |||
| Laboratory abnormalities | 46 (41.4) | 28 (52.8) | 18 (31.0) |
| Prior cellular therapies | 41 (36.9) | 21 (39.6) | 20 (34.4) |
| ECOG PS score of ≥2 | 17 (15.3) | 9 (16.9) | 8 (13.7) |
| CNS pathology | 13 (11.7) | 6 (11.3) | 7 (12.0) |
| Cardiac dysfunction | 16 (14.4) | 4 (7.5) | 12 (20.6) |
| Anti-MM therapy within 2 wk of leukapheresis | 14 (12.6) | 7 (13.2) | 7 (12.0) |
| Active or history of PCL, POEMS, malignancy, etc | 20 (18.0) | 10 (18.8) | 10 (17.2) |
| RI | 18 (16.2) | 6 (11.3) | 12 (20.6) |
| Infections | 7 (6.3) | 5 (9.4) | 2 (3.4) |
| Significant medical, laboratory, or psychiatric events | 11 (9.9) | 8 (15.0) | 3 (5.1) |
| Nonsecretory MM | 6 (5.4) | 5 (9.4) | 1 (1.7) |
| Others | 1 (0.9) | 0 (0.0) | 1 (1.7) |
| . | Total . | Age of <65 y . | Age of ≥65 y . |
|---|---|---|---|
| Number of patients, n (%) | 156 | 81 (51.9) | 75 (48.0) |
| Comorbidity burden | |||
| No comorbidities | 7 (4.3) | 5 (5.9) | 2 (2.5) |
| ≥1 comorbidity | 149 (95.7) | 76 (94.0) | 73 (97.5) |
| Total comorbidities | 147 | 87 | 102 |
| Frequent comorbidities (>10% in patient population) | |||
| Neuropathy | 80 (51.2) | 36 (44.4) | 44 (58.6) |
| Hypertension | 56 (35.8) | 23 (28.3) | 33 (44.0) |
| Pain | 53 (33.9) | 23 (28.3) | 30 (40.0) |
| Diabetes | 28 (17.9) | 13 (16.0) | 15 (20.0) |
| Hyperlipidemia | 26 (16.6) | 10 (12.3) | 16 (21.3) |
| Immunodeficiency | 25 (16.0) | 10 (12.3) | 15 (20.0) |
| Renal dysfunction∗ | 22 (14.1) | 9 (11.1) | 13 (17.3) |
| GERD | 18 (11.5) | 10 (12.3) | 8 (10.6) |
| Anxiety | 18 (11.5) | 11 (13.5) | <10% |
| Depression | <10% | 11 (13.5) | <10% |
| Arthritis | <10% | 9 (11.3) | <10% |
| Anemia | <10% | <10% | 9 (12.0) |
| Hypothyroidism | <10% | <10% | 8 (10.6) |
| OSA | <10% | <10% | 8 (10.6) |
| Did not meet KarMMa trial criteria | 111 (71.1) | 53 (65.4) | 58 (77.3) |
| Individual KarMMa trial exclusion criteria | |||
| Laboratory abnormalities | 46 (41.4) | 28 (52.8) | 18 (31.0) |
| Prior cellular therapies | 41 (36.9) | 21 (39.6) | 20 (34.4) |
| ECOG PS score of ≥2 | 17 (15.3) | 9 (16.9) | 8 (13.7) |
| CNS pathology | 13 (11.7) | 6 (11.3) | 7 (12.0) |
| Cardiac dysfunction | 16 (14.4) | 4 (7.5) | 12 (20.6) |
| Anti-MM therapy within 2 wk of leukapheresis | 14 (12.6) | 7 (13.2) | 7 (12.0) |
| Active or history of PCL, POEMS, malignancy, etc | 20 (18.0) | 10 (18.8) | 10 (17.2) |
| RI | 18 (16.2) | 6 (11.3) | 12 (20.6) |
| Infections | 7 (6.3) | 5 (9.4) | 2 (3.4) |
| Significant medical, laboratory, or psychiatric events | 11 (9.9) | 8 (15.0) | 3 (5.1) |
| Nonsecretory MM | 6 (5.4) | 5 (9.4) | 1 (1.7) |
| Others | 1 (0.9) | 0 (0.0) | 1 (1.7) |
KarMMa trial inclusion and exclusion criteria detailed in supplemental Materials.
CNS, central nervous system; GERD, gastroesophageal reflux disease; OSA, obstructive sleep apnea; PCL, plasma cell leukemia; POEMS, polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes.
Renal dysfunction: acute kidney disease, or chronic kidney disease, or renal insufficiency.